Prosecution Insights
Last updated: April 19, 2026
Application No. 17/069,726

METHOD FOR INDUCING ANGIOGENESIS

Non-Final OA §102§103§112
Filed
Oct 13, 2020
Examiner
DAVIS, RUTH A
Art Unit
1699
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Mimedx Group Inc.
OA Round
5 (Non-Final)
61%
Grant Probability
Moderate
5-6
OA Rounds
3y 4m
To Grant
92%
With Interview

Examiner Intelligence

Grants 61% of resolved cases
61%
Career Allow Rate
540 granted / 889 resolved
+0.7% vs TC avg
Strong +31% interview lift
Without
With
+30.9%
Interview Lift
resolved cases with interview
Typical timeline
3y 4m
Avg Prosecution
45 currently pending
Career history
934
Total Applications
across all art units

Statute-Specific Performance

§101
3.9%
-36.1% vs TC avg
§103
33.3%
-6.7% vs TC avg
§102
18.8%
-21.2% vs TC avg
§112
30.3%
-9.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 889 resolved cases

Office Action

§102 §103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on October 28, 2025 has been entered. Claims 43 – 44 are added; claims 17, 27 – 30, 33 – 38 and 40 – 44 are pending and have been considered on the merits. Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 17, 27 – 30, 33 – 38 and 40 – 44 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. Claim 17 recites a method for inducing angiogenesis wherein the method requires a step of extracting placental growth factors from amniotic basement membrane. The specification does not describe this step as originally filed. Rather, the specification teaches extracting growth factors from a placental tissue, specifically an amnion/chorion membrane which includes a basement membrane. The specification recites “basement membrane” in three occurrences: 1) the amnion is placed basement membrane layer down (0053, PgPubs); 2) the basement membrane is exposed (0056, PgPubs); and 3) the basement membrane is intact post de-epithelialization (0058, PgPubs). However, the specification fails to identify or describe any method step of extracting growth factors from a basement membrane alone as newly claimed. This is a new mater rejection. Claim Rejections - 35 USC § 102 Previous rejections under 35 U.S.C. 102a1 as being anticipated by Kihm are withdrawn due to applicant’s amendment requiring a step for extracting placental growth factors from an amniotic basement membrane. Claim Rejections - 35 USC § 103 Previous rejections under 35 U.S.C. 103 as being unpatentable over Kihm are withdrawn due to applicant’s amendment requiring a step for extracting placental growth factors from an amniotic basement membrane. No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to RUTH A DAVIS whose telephone number is (571)272-0915. The examiner can normally be reached Monday - Friday (8am - 4pm). Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Fereydoun Sajjadi can be reached on 571-272-3311. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /RUTH A DAVIS/ Primary Examiner, Art Unit 1699
Read full office action

Prosecution Timeline

Oct 13, 2020
Application Filed
Aug 26, 2023
Non-Final Rejection — §102, §103, §112
Jan 30, 2024
Response Filed
Mar 09, 2024
Final Rejection — §102, §103, §112
Aug 09, 2024
Response after Non-Final Action
Aug 14, 2024
Response after Non-Final Action
Sep 06, 2024
Request for Continued Examination
Sep 07, 2024
Response after Non-Final Action
Oct 07, 2024
Non-Final Rejection — §102, §103, §112
Mar 26, 2025
Response Filed
May 30, 2025
Final Rejection — §102, §103, §112
Aug 19, 2025
Interview Requested
Aug 26, 2025
Examiner Interview Summary
Aug 26, 2025
Applicant Interview (Telephonic)
Sep 25, 2025
Response after Non-Final Action
Oct 29, 2025
Response after Non-Final Action
Oct 29, 2025
Request for Continued Examination
Dec 12, 2025
Non-Final Rejection — §102, §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12599140
Agricultural compositions and methods for the delivery of plant health-promoting microbes
2y 5m to grant Granted Apr 14, 2026
Patent 12589125
YOGURT FOR REGULATING INTESTINAL TRACT, PREPARATION METHOD THEREFOR, AND USE THEREOF
2y 5m to grant Granted Mar 31, 2026
Patent 12584095
EXTRACELLULAR VESICLES FROM MICROALGAE
2y 5m to grant Granted Mar 24, 2026
Patent 12571790
BIOENERGETIC PROFILING OF CIRCULATING BLOOD CELLS AND SYSTEMS, DEVICES, AND METHODS RELATING THERETO
2y 5m to grant Granted Mar 10, 2026
Patent 12569462
Animal Feeds and Feed Premixes Containing Betaine and a Phytase
2y 5m to grant Granted Mar 10, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

5-6
Expected OA Rounds
61%
Grant Probability
92%
With Interview (+30.9%)
3y 4m
Median Time to Grant
High
PTA Risk
Based on 889 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month